RAPID Platform

JNANA HAS BUILT A NEXT GENERATION CHEMOPROTEOMIC PLATFORM TO SYSTEMATICALLY DEVELOP SMALL MOLECULE MEDICINES FOR ANY TARGET CLASS WITH UNPRECEDENTED SPEED.

An expansive opportunity to address previously undruggable targets.
Advances in genomics have bolstered our understanding of critical disease drivers, leading to well-validated protein targets, but the limitations of conventional drug discovery approaches have led to many of these targets remaining elusive.

Our RAPID platform brings hard-to-drug targets within reach.
Jnana has built a proprietary Reactive Affinity Probe Interaction Discovery (RAPID) platform that enables an unprecedented interrogation of target proteins to reveal any druggable site and identify promising drug-like molecules with unprecedented speed and efficiency.

RAPID is a proprietary ligand discovery platform that identifies small molecule binders irrespective of the fold or function of the target protein, delivering high quality, chemical starting points for programs.

Our platform is a ‘plug-and-play’ technology that is based on three core capabilities:

Jnana’s rapid platform enables efficient discovery of druggable sites, assessment of probe binding and screening of drug molecules.

 

 

We are removing barriers to reimagine what’s possible and accelerate drug discovery.
With our RAPID platform, we can address a range of challenging target classes, including SLC transporters, signaling scaffold proteins, transcription factors, phosphatases, and helicases. These targets are highly diverse, can be difficult to express and purify, and often have no known ligandable sites.

RAPID provides an unbiased approach for tackling challenging targets by identifying small molecule modulators based only on their ability to bind the protein. This binding-based approach provides deep insights into highly varied target binding sites and a broad opportunity to address targets across modalities due to the binders’ potential for diverse pharmacology, including effects on protein-protein interactions, post-translational modifications, sub-cellular localization, or protein half-life – in addition to canonical inhibition.

High-value targets with validated human biology remain elusive. Jnana is using our RAPID platform to advance drug-discovery programs in our internal pipeline and in collaborations with biopharma partners to systematically address these hard-to-drug targets and develop transformative small molecule therapeutics in rare genetic diseases, immune-mediated diseases and oncology.

Back to Top
 

This links to an external website. Merus is not responsible for any third party content.

Continue